RPG Life Sciences Limited — Earnings Release 2025

Jul 19, 2024

==> picture [426 x 28] intentionally omitted <==

==> picture [426 x 28] intentionally omitted <==

==> picture [426 x 10] intentionally omitted <==

July 19, 2024

The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limited Floor 25, P.J. Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No. C-1, G- Block, Mumbai 400 001 Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2024.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited

==> picture [184 x 37] intentionally omitted <==

Rajesh Shirambekar Head – Legal & Company Secretary

==> picture [71 x 73] intentionally omitted <==

Encl.: as above

==> picture [69 x 33] intentionally omitted <==

==> picture [160 x 62] intentionally omitted <==

Q1 FY25: Revenue Up by 12% Y-o-Y and 30% Q-o-Q. PBT Surges 21% Y-o-Y and 103% Q-o-Q, EBITDA Margin Hits 25.1%.

Mumbai, 19 July, 2024 : RPG Life Sciences Limited has announced its unaudited financial results for the quarter ended June 30, 2024.

Q1 FY25 Highlights	Y-o-Y Revenue from operationsY-o-Y PBT	Y-o-Y Revenue from operationsY-o-Y PBT
	Rs 165.42 crores – up from Rs 147.78 crores	Rs 36.00 crores – up from Rs 29.77 crores

RPG Life Sciences, a part of RPG Group, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT of 21% Y-o-Y and 103% Q-o-Q for Q1 FY25. Revenue from operations registered a growth of 12% Y-o-Y and a growth of 30% Q-o-Q at Rs 165.42 crores for Q1 FY25. The Company maintained an upward trajectory in EBITDA margin, which improved from 23.0% to 25.1% Y-o-Y.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q1 FY25, the overall performance of the Company continued to be strong. Revenue and PBT grew by 12% and 21% respectively Y-o-Y. Retaining its 5-year upward trajectory, the EBITDA margin crossed the 25% mark (25.1% up from 23.0% last year).

Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market - building some of our iconic “Textbook” brands like Naprosyn into megabrands through a comprehensive life cycle management program, shaping one successful product into a multi-product portfolio by leveraging our existing strong customer franchise, building the futuristic portfolio of MABs into a formidable product segment through multibranding strategy, replicating our smart and successful Rheumatology portfolio entry strategy to enter more specialties like Gastro and Derma, and deploying digital and productivity enhancement measures to ensure consistent salesforce productivity gains year-after-year.

We are now shaping our International Formulations and API businesses to emerge as second and third growth engines. For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth and the API business is also showing promising growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest-growing business groups with a turnover of US$ 4.4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Priya Singh – 81690 22988 | priya@rpg.in

==> picture [134 x 28] intentionally omitted <==